{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Immunic, Inc. "},"Symbol":{"label":"Symbol","value":"IMUX"},"Address":{"label":"Address","value":"11440 WEST BERNARDO COURT,SUITE 300, SAN DIEGO, California, 92127, United States"},"Phone":{"label":"Phone","value":"+49 89 2500794 60"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Immunic Inc is a clinical stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, IMU-935 is an inverse agonist of RORyt and IMU-856 targets the restoration of the intestinal barrier function."},"CompanyUrl":{"label":"Company Url","value":"https://www.imux.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andreas Muehler","title":"Chief Medical Officer"},{"name":"Daniel Vitt","title":"Chief Executive Officer & Director"},{"name":"Hella Kohlhof","title":"Chief Scientific Officer"},{"name":"Jason Tardio","title":"President & Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}